AIM: To investigate biological prevention with flavonoids the recurrence risk of neoplasia was studied in patients with resected colorectal cancer and after adenoma polypectomy. METHODS: Eighty-seven patients, 36 patients with resected colon cancer and 51 patients after polypectomy, were divided into 2 groups: one group was treated with a flavonoid mixture (daily standard dose 20 mg apigenin and 20 mg epigallocathechin-gallat, n = 31) and compared with a matched control group (n = 56). Both groups were observed for 3-4 years by surveillance colonoscopy and by questionnaire. RESULTS: Of 87 patients enrolled in this study, 36 had resected colon cancer and 29 of these patients had surveillance colonoscopy. Among the flavonoid-treated patients with resected colon cancer (n = 14), there was no cancer recurrence and one adenoma developed. In contrast the cancer recurrence rate of the 15 matched untreated controls was 20% (3 of 15) and adenomas evolved in 4 of those patients (27%). The combined recurrence rate for neoplasia was 7% (1 of 14) in the treated patients and 47% (7 of 15) in the controls (P = 0.027). CONCLUSION: Sustained long-term treatment with a flavonoid mixture could reduce the recurrence rate of colon neoplasia in patients with resected colon cancer.
AIM: To investigate biological prevention with flavonoids the recurrence risk of neoplasia was studied in patients with resected colorectal cancer and after adenoma polypectomy. METHODS: Eighty-seven patients, 36 patients with resected colon cancer and 51 patients after polypectomy, were divided into 2 groups: one group was treated with a flavonoid mixture (daily standard dose 20 mg apigenin and 20 mg epigallocathechin-gallat, n = 31) and compared with a matched control group (n = 56). Both groups were observed for 3-4 years by surveillance colonoscopy and by questionnaire. RESULTS: Of 87 patients enrolled in this study, 36 had resected colon cancer and 29 of these patients had surveillance colonoscopy. Among the flavonoid-treated patients with resected colon cancer (n = 14), there was no cancer recurrence and one adenoma developed. In contrast the cancer recurrence rate of the 15 matched untreated controls was 20% (3 of 15) and adenomas evolved in 4 of those patients (27%). The combined recurrence rate for neoplasia was 7% (1 of 14) in the treated patients and 47% (7 of 15) in the controls (P = 0.027). CONCLUSION: Sustained long-term treatment with a flavonoid mixture could reduce the recurrence rate of colon neoplasia in patients with resected colon cancer.
Authors: Monica M Bertagnolli; Craig J Eagle; Ann G Zauber; Mark Redston; Scott D Solomon; KyungMann Kim; Jie Tang; Rebecca B Rosenstein; Janet Wittes; Donald Corle; Timothy M Hess; G Mabel Woloj; Frédéric Boisserie; William F Anderson; Jaye L Viner; Donya Bagheri; John Burn; Daniel C Chung; Thomas Dewar; T Raymond Foley; Neville Hoffman; Finlay Macrae; Ronald E Pruitt; John R Saltzman; Bruce Salzberg; Thomas Sylwestrowicz; Gary B Gordon; Ernest T Hawk Journal: N Engl J Med Date: 2006-08-31 Impact factor: 91.245
Authors: Marcia Cruz-Correa; Daniel A Shoskes; Patricia Sanchez; Rhongua Zhao; Linda M Hylind; Steven D Wexner; Francis M Giardiello Journal: Clin Gastroenterol Hepatol Date: 2006-06-06 Impact factor: 11.382
Authors: Marta Rossi; Eva Negri; Renato Talamini; Cristina Bosetti; Maria Parpinel; Patrizia Gnagnarella; Silvia Franceschi; Luigino Dal Maso; Maurizio Montella; Attilio Giacosa; Carlo La Vecchia Journal: Cancer Epidemiol Biomarkers Prev Date: 2006-08 Impact factor: 4.254
Authors: Song-Yi Park; Suzanne P Murphy; Lynne R Wilkens; Abraham M Y Nomura; Brian E Henderson; Laurence N Kolonel Journal: Am J Epidemiol Date: 2007-01-10 Impact factor: 4.897
Authors: Jennifer Lin; Shumin M Zhang; Kana Wu; Walter C Willett; Charles S Fuchs; Edward Giovannucci Journal: Am J Epidemiol Date: 2006-08-21 Impact factor: 4.897
Authors: Sidney J Winawer; Ann G Zauber; Robert H Fletcher; Jonathon S Stillman; Michael J O'Brien; Bernard Levin; Robert A Smith; David A Lieberman; Randall W Burt; Theodore R Levin; John H Bond; Durado Brooks; Tim Byers; Neil Hyman; Lynne Kirk; Alan Thorson; Clifford Simmang; David Johnson; Douglas K Rex Journal: Gastroenterology Date: 2006-05 Impact factor: 22.682
Authors: Douglas K Rex; Charles J Kahi; Bernard Levin; Robert A Smith; John H Bond; Durado Brooks; Randall W Burt; Tim Byers; Robert H Fletcher; Neil Hyman; David Johnson; Lynne Kirk; David A Lieberman; Theodore R Levin; Michael J O'Brien; Clifford Simmang; Alan G Thorson; Sidney J Winawer Journal: Gastroenterology Date: 2006-05 Impact factor: 22.682
Authors: Jürgen Weitz; Moritz Koch; Jürgen Debus; Thomas Höhler; Peter R Galle; Markus W Büchler Journal: Lancet Date: 2005 Jan 8-14 Impact factor: 79.321
Authors: Evropi Theodoratou; Janet Kyle; Roseanne Cetnarskyj; Susan M Farrington; Albert Tenesa; Rebecca Barnetson; Mary Porteous; Malcolm Dunlop; Harry Campbell Journal: Cancer Epidemiol Biomarkers Prev Date: 2007-04 Impact factor: 4.254
Authors: Tety Leonardi; Jairam Vanamala; Stella S Taddeo; Laurie A Davidson; Mary E Murphy; Bhimanagouda S Patil; Naisyin Wang; Raymond J Carroll; Robert S Chapkin; Joanne R Lupton; Nancy D Turner Journal: Exp Biol Med (Maywood) Date: 2010-06
Authors: Simone Jacobs; Brook E Harmon; Nicholas J Ollberding; Lynne R Wilkens; Kristine R Monroe; Laurence N Kolonel; Loic Le Marchand; Carol J Boushey; Gertraud Maskarinec Journal: J Nutr Date: 2016-08-10 Impact factor: 4.798